Overview of the Biologic Markers of Breast Cancer

Porter-Jordan, K.; Lippman, Marc E.

doi:10.1016/s0889-8588(18)30188-6

Cited by 65 publications

(45 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have examined predictive and prognostic factors, such as the age of the patient, tumour size, grade, proliferation, hormone status, histological type of the tumour, and lymph node involvement, to name a few [6][7][8][9][10][11]. With the advancement in science and technology, molecular markers have been added to the above list, in an attempt to help the clinicians to better monitor the course of the disease and predict its outcome [10]. In this study, we conducted a comprehensive analysis of breast carcinomas taken from 166 patients in Kuwait.…”

Section: Discussionmentioning

confidence: 99%

Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis

Saleh¹,

Abdeen²

2008

European Journal of Cancer Supplements

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis

Saleh¹,

Abdeen²

2008

European Journal of Cancer Supplements

View full text Add to dashboard Cite

“…1 Most of the studies to date have concentrated on the MAGE and Erb-b2 families of tumor-associated genes in a variety of cancers. [2][3][4][5][6] With the exception of the Her-2/neu and BRCA-1/2 oncogenes, there is only limited information available regarding the involvement of other genes in breast cancer.…”

mentioning

confidence: 99%

Identification of HLA‐A3‐restricted CD8+ T cell epitopes derived from mammaglobin‐A, a tumor‐associated antigen of human breast cancer

Jaramillo

Majumder

Manna

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Mammaglobin-A is highly overexpressed in breast cancer cell lines and primary breast tumors. This pattern of expression is restricted to mammary epithelium and metastatic breast tumors. Thus, mammaglobin-A-specific T cell immune responses may provide an important approach for the design of breast cancer-specific immunotherapy. The purpose of our study was to define the T cell-mediated immune response to mammaglobin-A. We determined that the frequency of mammaglobin-A-reactive CD8؉ and CD4؉ T cells in breast cancer patients is significantly higher than that observed in healthy female controls using limiting dilution analyses (p ‫؍‬ 0.026 and p ‫؍‬ 0.02, respectively). We identified

show abstract

“…Gene amplification and overexpression of intact or wild type (wt)EGFR have been found in a variety of epithelial and neuronal neoplasms including squamous cell carcinomas, melanoma, and glioblastoma multiforme and portend a poor prognosis for patients with these tumors (13)(14)(15)(16). Overexpression of EGFR has been associated with a relative resistance to chemotherapy in cell lines and in patients with breast, ovarian, and esophageal cancer (17)(18)(19)(20)(21). HER2 is a closely related member of the EGFR family which is oncogenic when overexpressed in several cell contexts as a result of transactivation of HER2 complexes (22).…”

mentioning

confidence: 99%

Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters β-Tubulin Isotype Expression

Montgomery¹,

Guzman²,

O’Rourke³

et al. 2000

Journal of Biological Chemistry

103

View full text Add to dashboard Cite

Oncogenic transformation confers resistance to chemotherapy through a variety of mechanisms, including suppression of apoptosis, increased drug metabolism, and modification of target proteins. Oncogenic epidermal growth factor receptor family members, including EGFRvIII and HER2, are expressed in a broad spectrum of human malignancies. Cell lines transfected with EGFRvIII and HER2 are more resistant to paclitaxelmediated cytotoxicity, and tubulin polymerization induced by paclitaxel is suppressed compared with cells expressing wild type epidermal growth factor receptor. Because differential expression of ␤-tubulin isotypes has been proposed to modulate paclitaxel resistance, we analyzed ␤-tubulin isotypes expressed in cell lines transfected with different oncogenes. EGFRvIII-and HER2-expressing cells demonstrated equivalent total ␤-tubulin protein compared with cells transfected with wild type receptor or untransfected controls. EGFRvIII-expressing cells demonstrated increases in class IVa (2.5-fold) and IVb (3.1-fold) mRNA, and HER2-expressing cells showed increases in class IVa (2.95-fold) mRNA. Expression of oncogenic Ha-Ras did not change class IV RNA levels significantly. Inhibition of EGFRvIII kinase activity using a mutant allele with an inactivating mutation in the kinase domain decreased expression of class IVa by 50% and partially reversed resistance to paclitaxel. Expression of oncogenic epidermal growth factor receptor family members is associated with modulation of both ␤-tubulin isotype expression and paclitaxel resistance in cells transformed by expression of the receptor. This effect on tubulin expression may modulate drug resistance in human malignancies that express these oncogenes.

show abstract

Overview of the Biologic Markers of Breast Cancer

Cited by 65 publications

References 116 publications

Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis

Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis

Identification of HLA‐A3‐restricted CD8+ T cell epitopes derived from mammaglobin‐A, a tumor‐associated antigen of human breast cancer

Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters β-Tubulin Isotype Expression

Contact Info

Product

Resources

About